CytoMed Therapeutics (GDTC) Current Taxes (2022 - 2023)
CytoMed Therapeutics (GDTC) posted Current Taxes of $483.67 for Q4 2023, down 68.14% sequentially from $1518.0 in Q2 2023, and down 59.07% YoY from $1181.7 in Q4 2022.
CytoMed Therapeutics (GDTC) Current Taxes (2022 - 2023) Analysis & Trends
CytoMed Therapeutics has reported Current Taxes for 2 years, with the latest figure at $483.67 in Q4 2023.
- Quarterly Current Taxes fell 59.07% year-over-year to $483.67 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $483.67 (down 59.07% YoY) and the FY2023 annual result came in at $486.36, down 59.13% from the prior year.
- Current Taxes retreated to $483.67 in Q4 2023 per GDTC's latest filing, from $1518.0 in the prior quarter.
- Over five years, Current Taxes peaked at $1518.0 in Q2 2023 and troughed at $483.67 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.51 Bn | 78.51 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 65.74 Bn | 60.56 Bn | 1.37 Bn | 49.00 Mn |
| 4 | Moderna | 59.39 Bn | 54.26 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.24 Bn | 37.15 Bn | 1.53 Bn | 76.32 Mn |
| 6 | Alnylam Pharmaceuticals | 31.78 Bn | 28.47 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | 76.36 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.22 Bn | 26.39 Bn | - | - |
| 10 | CytoMed Therapeutics | 9.97 Mn | 8.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 483.67 |
| Jun 30, 2023 | 1,518.00 |
| Dec 31, 2022 | 1,181.72 |